Trial Profile
Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms MILES-3
- 23 Mar 2023 Planned End Date changed from 1 Nov 2021 to 1 Nov 2024.
- 23 Mar 2023 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2024.
- 03 Mar 2021 Planned End Date changed from 1 Sep 2018 to 1 Nov 2021.